1. Introduction {#sec1-pharmaceutics-12-00602}
===============

The first concepts of tissue engineering (TE) were proposed by Langer et al. \[[@B1-pharmaceutics-12-00602]\] where the idea was to expand cells of a given patient *in vitro* prior seeding them into a synthetic or natural scaffold followed by the implantation of this cellularized scaffold back to the patient. TE appears as a promising way to regenerate a part of the body which has been lost or damaged after trauma or diseases, especially for large defects and for poorly vascularized tissues having limited healing capacities such as cartilage. Many researchers used to generate porous scaffolds for tissue regeneration where the scaffold acts as an extracellular matrix (ECM) substitute for cells allowing them to adhere, proliferate, and to differentiate while the scaffold is gradually degraded and replaced by a new tissue. This is mainly based on the fact that many types of materials appeared to be biocompatible. Even though the definition of biocompatibility is still unclear depending on whether studies are conducted *in vitro* or *in vivo*, it is generally accepted that a material is considered as biocompatible as long as it does not promote any acute toxicity or alteration of cell functions \[[@B2-pharmaceutics-12-00602]\]. Furthermore, a large number of ways to form these scaffolds already exist (foaming, electrospinning, salt leaching, additive manufacturing, self-assembly, etc.), offering many options to tailor the structure of the scaffold according to the targeted application. Tissue engineering's market is estimated to reach USD 11.5 million in 2022 \[[@B3-pharmaceutics-12-00602]\].

Scaffolds offer a three-dimensional environment to cells which was already shown to modify the genetic expression and shape of cells compared to flat surfaces \[[@B4-pharmaceutics-12-00602]\] and the architecture of scaffolds can influence cell fate such as their proliferation or their ability to colonize the structure. Moreover, the substrate chemistry or topography impacts the adhesiveness, and later on, the proliferation of cells and the addition of soluble molecules such as growth factors or hormones contributes as well to the overall cellular response \[[@B5-pharmaceutics-12-00602],[@B6-pharmaceutics-12-00602]\]. However it is not straightforward to determine whether cell response into a three-dimensional structure is mainly driven by the cell--substrate interaction or by the macro structure of the scaffold since cells can probe their environment at different levels ranging from the nanoscale such as protein conformation with which they interact within the ECM and up to the macroscale corresponding to the global tissue organization \[[@B7-pharmaceutics-12-00602],[@B8-pharmaceutics-12-00602]\]. Therefore, the main parameters which can lead to full scaffold integration and sustain cell functions remain unclear. Consequently, this review firstly summarizes the main materials used in TE and their techniques of fabrication. Thereafter, focusing on the interaction between the scaffold architecture solely namely: pore and interconnection sizes, porosity, and mechanical properties and the associated cell response before reviewing the impact of bioactive scaffolds where biological cues are supplemented to the scaffold. The idea is to investigate if structural parameters can be enough to control tissue growth compared to bioactive scaffolds providing signaling molecules and other cues interacting with cells. Numerous studies were already conducted, trying several conditions to promote tissue growth emanating various conclusions. This review aims to evaluate the degree of complexity required to generate an ideal scaffold gathering the most relevant parameters that drive tissue regeneration. Finally, the main feedbacks of *in vivo* studies will be provided to highlight the main successes while emphasizing future challenges to continue to improve the integration of implantable scaffolds in the body.

2. Overview of the Techniques Used for Fabrication of Porous Scaffolds for Tissue Engineering Applications {#sec2-pharmaceutics-12-00602}
==========================================================================================================

Scaffolds have been generated by numerous techniques offering various degrees of flexibility according to the final application (i.e., type of cell hosted, soft or hard tissues, load-bearing locations or not). Ideally, the obtained scaffold must provide a well-balanced environment between mechanical properties, high specific surface area, good diffusivity and being well interconnected to support and sustain cell functions. An overview of the most frequently used techniques of preparation and the resulting scaffolds will be given here along with their many advantages and limitations for tissue engineering applications.

2.1. Electrospinning {#sec2dot1-pharmaceutics-12-00602}
--------------------

Electrospun assemblies are obtained by applying an electric field to a charged polymer solution which is propelled to a static or non-static collector either oppositely charged or grounded \[[@B9-pharmaceutics-12-00602]\]. Highly fibrous structures can therefore be obtained having similarities with the native ECM ([Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}a,b). The fiber morphology and size can be controlled through various parameters such as polymer type and solution concentration, voltage applied, collector-to-needle tip distance, and conductivity of the polymeric solution \[[@B10-pharmaceutics-12-00602],[@B11-pharmaceutics-12-00602]\] ([Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}c). Polymers, both natural and synthetic, are widely employed in electrospinning due to their relatively low melting temperature and ease to process \[[@B12-pharmaceutics-12-00602]\]. Additionally, electrospun scaffolds can be functionalized in order to incorporate relevant properties such as biodegradability or drug release \[[@B13-pharmaceutics-12-00602],[@B14-pharmaceutics-12-00602],[@B15-pharmaceutics-12-00602]\]. Furthermore, the control over mechanical properties of the fibrous structure can also be achieved \[[@B16-pharmaceutics-12-00602],[@B17-pharmaceutics-12-00602],[@B18-pharmaceutics-12-00602]\]. However, even though a tight packing of the fibers allows to maintain an acceptable mechanical strength, the high fiber density leads to structures with small pores which consequently limits the cellular infiltration throughout the overall scaffold \[[@B19-pharmaceutics-12-00602]\]. Another consequence that follows the previous statement is the reduction of the transport properties across the whole volume, hampering an efficient supply of nutrients and oxygen to cells \[[@B20-pharmaceutics-12-00602]\]. Thereby, electrospinning appears as a biomimetic approach to produce ECM-like assemblies with high surface-to-volume ratios, but the balance between mechanical properties and porosity needs to be adjusted to guarantee an efficient colonization of cells. Interestingly, Kuo et al. \[[@B21-pharmaceutics-12-00602]\] recently developed a co-electrospinning system where fibers of two types were intertwined. After selective dissolution of one type of fiber, the interstitial space was increased, showing beneficial effects on cell growth.

2.2. Additive Manufacturing {#sec2dot2-pharmaceutics-12-00602}
---------------------------

Additive manufacturing, which includes 3D printing, selective laser sintering (SLS) or stereolithography, among others \[[@B22-pharmaceutics-12-00602]\], groups a set of techniques where some material is added during the process conversely to etching whose process relies on material removal during the process. Additive manufacturing is standardized by the American Society for Testing and Materials (ASTM) F2792. This technique allows for the rational design of porous materials where the interconnection sizes, pore shapes, and the porosity can be controlled independently, which represents a major advantage for scaffold engineering \[[@B23-pharmaceutics-12-00602]\]. Moreover, this technology can be employed for numerous types of materials ranging from ceramics, polymers, metals and composites \[[@B24-pharmaceutics-12-00602]\]. Therefore, scaffolds can be designed for a broad range of applications such as tendons \[[@B25-pharmaceutics-12-00602]\] muscles \[[@B26-pharmaceutics-12-00602]\], bones \[[@B27-pharmaceutics-12-00602],[@B28-pharmaceutics-12-00602]\], and cartilage \[[@B29-pharmaceutics-12-00602]\]. Furthermore, direct printing of cells jointly with the scaffold shows promising results, especially regarding the homogenous distribution of cells within the printed scaffold that is achieved \[[@B30-pharmaceutics-12-00602],[@B31-pharmaceutics-12-00602]\]. One major drawback of additive manufacturing techniques is the lack of control over the nano up to the macro scale of the final scaffold, which is important considering the multiscale interaction of cells with the surrounding tissues \[[@B32-pharmaceutics-12-00602]\].

2.3. Particles Leaching {#sec2dot3-pharmaceutics-12-00602}
-----------------------

Scaffolds obtained by particle leaching are based on an assembly of particles acting as a negative template. Afterwards, the liquid (generally a monomer, a polymer melt, or solution) is poured on the template and let to infiltrate and to solidify followed by the selective dissolution of the particle leaving a porous network ([Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}d). The final structure is an accurate reproduction of the initial template whose pore size and shape are fixed by the size and shape of the sacrificial particles which are typically salt \[[@B33-pharmaceutics-12-00602]\] ([Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}f) due to its high solubility in aqueous media and preventing the use of organic solvents. However, other sacrificial agents can be found in the literature, as for example, polymers \[[@B34-pharmaceutics-12-00602]\]. This simple approach provides the control on the pore size by fixing the size of the sacrificial agent which can be selected according to the needs, which are usually ranging from tens to hundreds of microns. Additionally, the size of the interconnections can also be controlled through merging of particles packed in the initial template. Different strategies were followed as the addition of an adhesive \[[@B35-pharmaceutics-12-00602]\], sintering \[[@B36-pharmaceutics-12-00602],[@B37-pharmaceutics-12-00602]\], or chemical dissolution \[[@B38-pharmaceutics-12-00602]\]. In all cases, the formation of a "neck" between adjacent particles leads to the formation of an interconnection in the porous material. Furthermore, the morphology of the final structure depends only on the morphology of the initial template, hence, a vast number of polymers can be used in this process. In one of our previous studies \[[@B37-pharmaceutics-12-00602]\], porous scaffolds where interconnection sizes were controlled in a predictive manner using a new theoretical model of sintering were generated. Nearly identical sacrificial agents such as microspheres can lead to highly homogenous structures (see [Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}g) which is more likely to be used to investigate the influence of the scaffold's structure on cell response \[[@B38-pharmaceutics-12-00602],[@B39-pharmaceutics-12-00602],[@B40-pharmaceutics-12-00602]\]. Thus, particle leaching is a simple and cheap method that can be used to generate scaffolds with controlled pore size, porosity, and interconnectivity as well. Additionally, the interconnectivity (i.e., the degree of interconnection) can be improved by using spherical particles where the jamming transition ensures the highest number of interconnection per single pore \[[@B41-pharmaceutics-12-00602]\].

2.4. Foaming {#sec2dot4-pharmaceutics-12-00602}
------------

The use of foams for tissue engineering applications is well-documented in the literature \[[@B42-pharmaceutics-12-00602]\]. Foams are mostly obtained from a liquid/viscoelastic matrix, whose solidification leads to the formation of gas bubbles as a side product. These bubbles are then trapped within the solidified matrix which forms a foam. This process is widely used in industry but is also used to fabricate scaffolds for tissue engineering \[[@B43-pharmaceutics-12-00602],[@B44-pharmaceutics-12-00602]\]. However, the control of architectural parameters including the pore size distribution, the porosity, and the interconnection size remain challenging, thus, the geometry of these scaffolds is rather random as shown in [Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}e. Conversely, a precise control of the pore size within the micrometric range can be reached through physical foaming and especially by microfluidics. In that case, bubbles are generated one by one in a chip and packed in a container where the bubble assembly forms an initially liquid foam which becomes solid after polymerization \[[@B45-pharmaceutics-12-00602],[@B46-pharmaceutics-12-00602],[@B47-pharmaceutics-12-00602]\]. One advantage of this individualized bubble formation is that the resulting foams have a narrow pore size distribution, therefore the final scaffolds are highly homogenous and reproducible. One can note the similar appearance between scaffolds generated via monodisperse sphere templating and those obtained through microfluidics ([Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}h vs. [Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}g). However, the absence of friction between bubbles formed by microfluidics (compared to solid spheres) allows to obtain highly crystalline structures displaying hexagonally close-packed arrangements \[[@B48-pharmaceutics-12-00602],[@B49-pharmaceutics-12-00602]\] ([Figure 1](#pharmaceutics-12-00602-f001){ref-type="fig"}h). In crystalline structures, the coordination number (i.e., the number of direct neighbors) is maximized and the resulting interconnectivity is therefore enhanced. The interconnectivity is likely to be related to mass transport properties and cell migration ability, implying that this parameter needs to be optimized \[[@B50-pharmaceutics-12-00602]\]. A few examples describing the formation of scaffolds through microfluidics are currently available. Costantini et al. \[[@B51-pharmaceutics-12-00602],[@B52-pharmaceutics-12-00602]\] confirmed that alginate scaffolds generated by microfluidics with monodisperse pore size distribution have an improved interconnectivity, and consequently, a better nutrient supply to cells compared to scaffolds prepared by chemical foaming. Furthermore, Dehli et al. \[[@B45-pharmaceutics-12-00602]\] generated a gelatin methacryloyl hydrogel-based foam using microfluidics bubbling to produce a macroporous and ordered hydrogel as a promising candidate as a scaffold for tissue engineering. Nevertheless, microfluidics bubbling is still at the early stages of development and many aspects need to be addressed in order to broaden its applications. Indeed, the stability of the initially liquid foam and the solidification time must be finely tuned to ensure an open cell foam. Moreover, the mechanism of pore opening (i.e., interconnection formation) is still unclear, thereby, the distinct control over pore and interconnection size cannot be guaranteed yet \[[@B53-pharmaceutics-12-00602],[@B54-pharmaceutics-12-00602]\].

2.5. Hydrogels {#sec2dot5-pharmaceutics-12-00602}
--------------

Hydrogels are scaffolds whose structure forms a fibrous and highly hydrated structure. They can be used as cell carriers where cells are directly embedded in the fibrous network. Micro-sized meshes can directly be assimilated as an ECM protein network offering a realistic support for cell growth. Hydrogels can be easily obtained by crosslinking a monomer solution either chemically \[[@B60-pharmaceutics-12-00602]\], under radiation \[[@B61-pharmaceutics-12-00602]\], but also by their self-assembling mechanisms \[[@B62-pharmaceutics-12-00602]\] or through an aggregation mechanism after protein denaturation \[[@B63-pharmaceutics-12-00602]\]. One can, for instance, find hydrogels based on alginate \[[@B64-pharmaceutics-12-00602]\], gelatin \[[@B65-pharmaceutics-12-00602]\], hydroxypropylmethyl cellulose \[[@B66-pharmaceutics-12-00602]\], or hybrid combinations of fibrinogen and polyethylene glycol \[[@B67-pharmaceutics-12-00602]\]. Hydrogel-based scaffolds can be generated by conventional technologies such as 3D printing \[[@B68-pharmaceutics-12-00602]\] and also can be coupled to a stiffer scaffold with superior mechanical stiffness \[[@B69-pharmaceutics-12-00602]\]. Moreover, supramolecular hydrogels such as self-assembled peptides (SAP)-based hydrogels can be formed enzymatically \[[@B70-pharmaceutics-12-00602]\] or spontaneously depending on the initial peptide sequence chosen \[[@B71-pharmaceutics-12-00602]\] whilst viscoelasticity can be introduced through non-covalent bonds \[[@B72-pharmaceutics-12-00602]\]. Recently, a hydrogel with high mechanical properties a non-swelling behavior that allowed cell proliferation was obtained from crosslinking of micelles at high density \[[@B73-pharmaceutics-12-00602]\]. Mechanical properties of hydrogels are also straightforward to handle, through initial monomer concentration \[[@B74-pharmaceutics-12-00602]\] or via the crosslinking density \[[@B75-pharmaceutics-12-00602]\]. Nevertheless, one major drawback associated with hydrogels is the limited diffusion of nutrients and oxygen throughout the dense fibrous network \[[@B76-pharmaceutics-12-00602],[@B77-pharmaceutics-12-00602]\]. Such limitations can be overcome by the insertion of macropores or channels in the hydrogel structure \[[@B45-pharmaceutics-12-00602],[@B78-pharmaceutics-12-00602]\], thereby, one can take advantage of the improved transport properties through macropores combined with the local mesh-like environment mimicking the ECM. Kostina et al. \[[@B79-pharmaceutics-12-00602]\] recently printed a porous gyroid structured hydrogel, with a high specific surface area and highly permissive properties for nutrient diffusion as well ([Figure 2](#pharmaceutics-12-00602-f002){ref-type="fig"}). However, mechanical properties of hydrogels are sometimes poor due to their highly hydrated nature especially when utilized for hard tissue applications \[[@B80-pharmaceutics-12-00602]\]. Another strategy to improve the supply of nutrients is the patterning of the hydrogel with factors involved in the vascularization process to sustain the nutrient supply for longer periods \[[@B81-pharmaceutics-12-00602]\]. Nano/micro hydrogel particles, also named as "nano/microgels", represent an alternative way to work on diffusion problems by increasing the surface-to-volume ratio. Nano/microgels are suitable either for cell or drug delivery systems which can be injected directly by a syringe allowing minimal invasion \[[@B82-pharmaceutics-12-00602],[@B83-pharmaceutics-12-00602]\].

3. Materials Used for Scaffold Compositions {#sec3-pharmaceutics-12-00602}
===========================================

3.1. Polymers {#sec3dot1-pharmaceutics-12-00602}
-------------

Synthetic polymers are widely used in TE and for medical devices since they can be produced in large quantities and are easy to process with low costs. Besides this, the structure--property relationship of polymers is well-established \[[@B84-pharmaceutics-12-00602]\]. Biodegradable polymers are intensively studied since scaffolds are expected to be eliminated from the body in time by allowing new tissue replacement. Among these, polyesters (R-COO-R') are interesting candidates since they are subject to hydrolysis \[[@B85-pharmaceutics-12-00602]\]. Polymer degradability is also related to other features such as crystallinity and molecular weight \[[@B86-pharmaceutics-12-00602]\]. Common examples which can be found in the literature are poly(methyl methacrylate) (PMMA), poly(lactic-co-glycolic acid) (PLGA), poly(ɛ-caprolactone) (PCL), polylactic acid (PLA), or poly(ethylene terephthalate) (PET) based scaffolds. According to the aim of application, implanted scaffolds are intended for long-term standing. In that case, polyethers (R-O-R') are more efficient to resist against hydrolysis and polytetrafluoroethylene (PTFE) poly(ether)urethane (PU), or poly(ethylene) glycol (PEG) are options. Nonetheless, implanted devices are subject to harsh conditions within the body and other degradation mechanisms occur, especially enzymatic-mediated ones. Vascular grafts are usually made with PTFE (Teflon^®^), whose fluorocarbon backbone is highly stable and antithrombotic \[[@B87-pharmaceutics-12-00602]\]. Moreover, peptides and proteins are polyamides which can also be found in nylon for example. Such materials own advantageous mechanical properties and flexibility due to their intra-molecular hydrogen bonding \[[@B88-pharmaceutics-12-00602]\]. Moreover, the surface of polymers can be functionalized by chemical and physical treatments to increase their biological activity \[[@B89-pharmaceutics-12-00602],[@B90-pharmaceutics-12-00602],[@B91-pharmaceutics-12-00602],[@B92-pharmaceutics-12-00602]\].

Polymers derived from natural sources, particularly those derived from extracellular matrix (ECM) are relevant materials for tissue engineering due to their intrinsic bioactivity along with their self-assembling ability \[[@B93-pharmaceutics-12-00602],[@B94-pharmaceutics-12-00602]\]. For instance, the conformation of fibronectin can orchestrate precisely the delivery of growth factors to cells as shown by Trujillo et al. \[[@B95-pharmaceutics-12-00602]\]. Therefore, natural polymers are biocompatible and can support and direct cellular functions unlike synthetic polymers, whose bioactivity often requires surface modifications. Fibrin, collagen, or polysaccharides are frequently used since they are biodegradable and mechanically stable \[[@B96-pharmaceutics-12-00602],[@B97-pharmaceutics-12-00602],[@B98-pharmaceutics-12-00602]\]. Moreover, additional functionalities can be grafted to peptides or protein fragments through amine and carboxylic groups. Hydrogels can be formed from naturally-derived polymers, which provide high water or biological fluids retention \[[@B99-pharmaceutics-12-00602],[@B100-pharmaceutics-12-00602],[@B101-pharmaceutics-12-00602]\]. One major drawback of natural polymers comes from the batch-to-batch variability, responsible for changes in chemical nature or in mechanical properties, rendering such systems difficult to process at large scales \[[@B102-pharmaceutics-12-00602]\]. Finally, supramolecular polymers based on reversible and non-covalent chemical bonds \[[@B103-pharmaceutics-12-00602]\] are emerging and provide unique properties to materials \[[@B104-pharmaceutics-12-00602]\]. For instance, peptides can spontaneously self-assemble in water via hydrogen bonding or π-π interactions leading to a three-dimensional network of self-assembled peptides (SAP). Accordingly, supramolecular chemistry provides a new route to generate SAP-based hydrogels whose benefits were already noticed for cell encapsulation and tissue engineering \[[@B105-pharmaceutics-12-00602],[@B106-pharmaceutics-12-00602]\]. Naskar et al. \[[@B107-pharmaceutics-12-00602]\] used two synthetic tetrapeptides, namely Gly-Phe-Ile-Leu and Gly-Ala-Ile-Leu, and defined how such oligopeptides self-assembled under pH variations ([Figure 3](#pharmaceutics-12-00602-f003){ref-type="fig"}).

3.2. Ceramics {#sec3dot2-pharmaceutics-12-00602}
-------------

Another class of materials used in tissue engineering are ceramics, which are inorganic composites that are usually brittle and hard, and they are mostly suitable for hard tissue applications \[[@B108-pharmaceutics-12-00602]\]. Based on their properties, they are categorized in three different classes, namely: bioinert, bioactive, and bioresorbable. Bioinert ceramics are commonly used at locations requiring high load-bearing abilities such as articulations. They have a good stability *in vivo* and therefore sustain their mechanical properties for long-term. These materials are widely employed for orthopedics \[[@B109-pharmaceutics-12-00602]\]. Aluminum oxide, zirconium oxide, and pyrolytic carbon are common examples. Bioactive ceramics can interact with their physiological environment by creating bonds with bones \[[@B110-pharmaceutics-12-00602]\], resulting in a better integration of implants \[[@B111-pharmaceutics-12-00602]\]. These ceramics can also be used as coatings of another based-material and are already commercialized, as for instance, Bioglass^®^ \[[@B112-pharmaceutics-12-00602]\]. The third class concerns bioresorbable ceramics, which can be dissolved under physiological conditions, or through cell-induced degradation mechanisms \[[@B113-pharmaceutics-12-00602]\]. The products of the dissolving reaction are non-toxic and the degradation rate is equivalent to the grow rate of the neo-tissue \[[@B114-pharmaceutics-12-00602]\]. Calcium phosphate is the most abundant type of bioresorbable ceramics including hydroxyapatite (Hap), which can be found in teeth and bones, and β-tricalcium phosphate (TCP) is also deeply investigated \[[@B115-pharmaceutics-12-00602]\].

3.3. Metals {#sec3dot3-pharmaceutics-12-00602}
-----------

Metals, whose elastic moduli is in the order of magnitude of metals, are widespread in the biomedical field, especially for bone tissue engineering. The immune reaction and especially the foreign body reaction (FBR) associated with metal implants or prosthetics is drastically lowered due to the spontaneously formed oxide layer at the outmost surface. Accordingly, potentially harmful effects such as fragments resulting from corrosion and ion release in the body are reduced \[[@B116-pharmaceutics-12-00602]\]. Common metals in tissue engineering are titanium and its associated alloys such as Nitinol and stainless steel. A large variety of available alloys is defined by the American Society for Testing and Materials (ASTM) and their respective composition is tightly related to their properties \[[@B117-pharmaceutics-12-00602]\]. Therefore, "shape memory" properties (i.e., the ability to recover the initial shape after being deformed under thermal variations) can be attributed. This is, for instance, the case for Nitinol \[[@B118-pharmaceutics-12-00602]\]. However, metal implants are sensitive to physiological environments as well as to repetitive stresses, which happen in articulations for instance, promoting fatigue and abrasion \[[@B119-pharmaceutics-12-00602],[@B120-pharmaceutics-12-00602]\]. According to their composition, alloys can slow down the degradation rate of the degradation process and resist against external stresses. Magnesium-based alloys whose residues are eliminated out of the body are a good example for this case \[[@B121-pharmaceutics-12-00602],[@B122-pharmaceutics-12-00602]\]. Metallic scaffolds can be generated by additive manufacturing technologies \[[@B123-pharmaceutics-12-00602],[@B124-pharmaceutics-12-00602]\], thereby, three dimensional structures with complex geometries can be achieved as demonstrated by Kolken et al. \[[@B125-pharmaceutics-12-00602]\] who produced an auxetic metal-based scaffold (i.e., with a negative value of the Poisson ratio) as a potential hip implant with compression resisting properties. Auxetic materials were already found to be efficient as esophageal stent for patients suffering from dysphagia \[[@B126-pharmaceutics-12-00602]\]. Besides, these materials usually have a hierarchically organized structure, which may be suitable for tissue engineering purposes, however, to our knowledge, there is no study in the literature showing the use of auxetic material-based scaffolds *in vitro*.

4. Review of the Influence of the Scaffold Architecture on Cell Behavior {#sec4-pharmaceutics-12-00602}
========================================================================

Porous three-dimensional environments provide several cues which can affect the ability of cells to sustain their functions. Moreover, the architecture of scaffolds such as the pore and interconnection size or the porosity was considered as an important element influencing mass transport and migration properties, vascularization potential and cellular organization. On the basis of mechanotransduction, external forces are transmitted through actin filaments and translated into biological signals toward the nucleus triggering various signalization pathways. Therefore, the mechanical properties of the based material along with the curved interface provided by the pore walls act as physical cues and thus play a role on cell fate. Below, we summarize the main correlations which have been established between the material structure and its influence on cell growth and fate within the produced scaffolds.

4.1. Effect of Porosity {#sec4dot1-pharmaceutics-12-00602}
-----------------------

Porosity is an indication of the void percentage of a porous structure and it affects cell growth. Porosity is defined as \[[@B127-pharmaceutics-12-00602]\]:$$P = 100 \times \left( {1 - \frac{\rho_{s}}{\rho_{b}}} \right),$$ where $\rho_{s}$ and $\rho_{b}$ are the densities of the scaffold and the bulk material, respectively. The Young's modulus $E_{s}$ of cellular materials is defined as \[[@B127-pharmaceutics-12-00602]\]:$$E_{s} = E_{b}\left( \frac{\rho_{s}}{\rho_{b}} \right)^{2},$$ where $E_{b}$ is the Young's modulus of the bulk material. Hence, from Equations (1) and (2), one can see that an increase in porosity is accompanied with a decrease in Young's modulus \[[@B128-pharmaceutics-12-00602],[@B129-pharmaceutics-12-00602]\]. Commonly, generated scaffolds have porosities ranging between 70 and 90% \[[@B130-pharmaceutics-12-00602],[@B131-pharmaceutics-12-00602]\]. Generally, scaffolds with low porosities have a larger surface area, which is more favorable for initial cell attachment, whereas scaffolds with large porosities, the cell density may be smaller and this delays cell proliferation \[[@B132-pharmaceutics-12-00602]\]. On one hand, a higher porosity is correlated with an increase in diffusivity of nutrients and a higher hydraulic permeability, but on the other hand, the loss in Young's modulus diminishes the mechanical properties of the scaffold \[[@B133-pharmaceutics-12-00602]\]. Furthermore, the decrease of the Young's modulus is higher for biodegradable materials since they lose their integrity during degradation \[[@B134-pharmaceutics-12-00602],[@B135-pharmaceutics-12-00602]\]. However, this effect can partially be counterbalanced by the newly synthesized ECM formed inside the scaffold, which reinforces the overall mechanical strength of the scaffold as it has been reported earlier for bone \[[@B136-pharmaceutics-12-00602]\]. Therefore, porosity value affects both the available surface area and the fluid transport properties which need to be finely balanced to obtain an optimized scaffold. For this purpose, Montazerian et al. \[[@B137-pharmaceutics-12-00602]\] demonstrated that triply periodic minimal structures (TPMS) (i.e., a structure whose the sum of the principal curvature at each point is zero \[[@B138-pharmaceutics-12-00602]\]) appear as promising candidates for scaffolds with large porosities and transport properties while keeping suitable mechanical properties. Moreover, complex geometries can be achieved, leading to hierarchically organized structures as shown in [Figure 4](#pharmaceutics-12-00602-f004){ref-type="fig"}.

4.2. Effect of Pore Size and Shape {#sec4dot2-pharmaceutics-12-00602}
----------------------------------

The diameter of pores in a porous scaffold is the main parameter which can be controlled by most of the used techniques and also probably the most widely studied one. As it has been shown to influence cell fate, in this section we will summarize main conclusions from the literature concerning the effect of pore size on cell behavior. In the below-mentioned studies, even if some exogenous factors were supplemented in some cases, their concentrations and exposure durations were kept constant for all testing conditions to ensure that the differences in cell behavior was only attributed to the varying parameter (i.e., pore size and shape). Matsiko et al. \[[@B139-pharmaceutics-12-00602]\] investigated the effect of the pore diameter of a scaffold on MSCs growth by comparing three different diameters in average namely: 94, 130, and 300 µm. Chondrogenic markers were significantly upregulated in scaffolds with the largest pore average diameter (300 µm) according to the secretions of type II collagen (COL2) and sulphated glycosaminoglycans (s-GAGs) after 28 days *in vitro*. These effects were attributed to the better access to nutrients and oxygen in the scaffold with the largest pores even though no quantification of transport properties was made. Besides, cells adopted different morphologies ranging from elongated and flattened in the smallest pores (94 µm) to rounded in scaffolds with the largest pores (300 µm). Conversely, the viability of human skin fibroblasts was improved in scaffolds whose pore diameters in average were either 74 or 160 µm compared to 194 and 381 µm after one week of culture \[[@B140-pharmaceutics-12-00602]\]. In another study, scaffolds with a pore diameter of 200 ± 85 µm were found to be optimal regarding tissue growth compared to 170 ± 80 µm, and 243 ± 95 µm-sized pores while the porosity was held fairly constant between 75 and 82% for all the scaffolds \[[@B141-pharmaceutics-12-00602]\]. The influence of the thickness of the scaffold was also investigated showing that thicker samples (4 mm) limited cell penetration at the center of the scaffold, which was unlikely for thinner ones (1.5 mm). Tissue like bone has a hierarchically organized structure where pore size and porosity change from cancellous to cortical bone. Di Luca et al. \[[@B142-pharmaceutics-12-00602]\] investigated cell growth in scaffolds with a pore diameter gradient ranging from 500 to 1100 µm and showed that ALP activity was higher in the largest pores, which was again justified by a better access to nutrients and oxygen. Interestingly, Heang Oh et al. \[[@B143-pharmaceutics-12-00602]\] demonstrated that a pore diameter range of 370 to 400 µm (compared to smaller pores in the range of 90--300 µm) was the most effective range to promote adipose stem cells chondrogenic differentiation using the same argument of nutrient accessibility. Even if in the last two examples, induction medium was added, the pore size effect contribution was distinguished as a key element involved in the differentiation process.

Globally, most of the studies come to agree on pore size ranging between 100 and 700 µm \[[@B144-pharmaceutics-12-00602]\]. The major argument relies on the transport properties throughout the whole scaffold which are lowered in scaffolds with smaller pore sizes since there is no flux such as the one of the interstitial fluid or blood stream which delivers nutrients continuously to cells. However, an implanted material will be in contact with many different cell types including immune cells such as macrophages or neutrophils. Macrophages were sensitive to the diameter of the pores in-vivo and pore diameters above 80 µm were shown to favor the pro-inflammatory type M1 macrophage polarization within the scaffold \[[@B145-pharmaceutics-12-00602]\]. Hence, this raises the question of the consistency between *in vitro* and *in vivo* studies regarding the optimal range of pore diameter that would guarantee suitable outcomes. Thereby, a screening of several cell types in response to a single scaffold may provide some insight on the overall cell behavior. Some work should be focused mainly on cells arriving at the implant site at the early stages after exposure to the body since the first cells in contact with the implant may recruit and secrete different factors which may subsequently determine and regulate the extend of the foreign body reaction (FBR). Moreover, the influence of pore size on cells is implicitly related to the pore shape \[[@B146-pharmaceutics-12-00602],[@B147-pharmaceutics-12-00602]\] and sometimes, the porosity (which evolves with pore size according to the fabrication process) as well. This multicomponent dependency makes it harder to isolate and quantify the contribution of a single parameter on cell fate. This is even more difficult when realizing that even if many studies have been held, the scaffold material, and thus the chemistry, the fabrication process, the cell type, and culture conditions differ in each case, making it difficult to accurately compare studies with each other.

4.3. Effect of Pore Interconnectivity {#sec4dot3-pharmaceutics-12-00602}
-------------------------------------

The interconnection is the aperture between two adjacent pores ([Figure 5](#pharmaceutics-12-00602-f005){ref-type="fig"}a) by which cells must go through in order to fully colonize a scaffold. Despite the fact that this parameter appears to be important regarding cell migration, the relationship between interconnection diameter and cell behavior is poorly documented in the literature compared to pore size and porosity \[[@B148-pharmaceutics-12-00602]\]. One reason is that the generation of scaffolds with controlled pore size and interconnectivity remains challenging and is not possible for most of the fabrication processes, although some approaches such as sphere templating and 3D printing allow it \[[@B34-pharmaceutics-12-00602],[@B149-pharmaceutics-12-00602]\].

In a previous study, sphere templating was employed to produce Beta-tricalcium phosphate (β-TCP) scaffolds where pore diameter was fixed (300--400 µm) and interconnection diameter was varied at 104 ± 13 µm, 117 ± 13 µm and 149 ± 12 µm, respectively \[[@B149-pharmaceutics-12-00602]\]. Scaffolds were seeded with human umbilical vein endothelial cells and the results demonstrated that for scaffolds with the largest interconnections (149 µm), the proliferation was the highest along with the PECAM-1 expression (maker for angiogenesis). The same trend was followed *in vivo* regarding the volume of blood vessels formed after 12 weeks in rabbits as shown in [Figure 5](#pharmaceutics-12-00602-f005){ref-type="fig"}b.

Somo et al. \[[@B40-pharmaceutics-12-00602]\] investigated the influence of two interconnection diameters (33 and 50 µm) for scaffolds having pore sizes ranging between 130 and 150 µm. Changes in the diameter of the interconnections led to modifications of the porosity values: 63% and 77%, respectively. After 3 weeks *in vivo*, scaffolds with the largest interconnections (50 µm) showed more benefits regarding tissue ingrowth, density, and homogeneity of the distribution of blood vessels in rodents. No statistical difference was found after 6 weeks regarding the blood vessel in-growth, which implies that interconnection diameters can enhance the kinetics of the colonization and vascularization of porous scaffolds.

Moreover, Choi et al. \[[@B150-pharmaceutics-12-00602]\] produced scaffolds by sphere templating to obtain porous materials with monodisperse or polydisperse pore size distributions. Accordingly, the scaffold with uniform pore diameter leads to a sharper size distribution of the interconnections. They demonstrated that a uniform size distribution of both pores and interconnections resulted in homogeneous cell distribution within the scaffold and to a higher nutrient supply as confirmed by measurements of the hydraulic permeability. The same conclusion was given by Costantini et al. \[[@B51-pharmaceutics-12-00602]\] for scaffolds generated by microfluidics.

The hydraulic permeability can be calculated by Darcy's law, which connects the velocity $V_{D}$ of a fluid flowing through the sample submitted to a pressure gradient providing the driving force of the flow \[[@B151-pharmaceutics-12-00602]\]. $$V_{D = -}k\frac{\rho g}{\eta}\frac{\mathsf{\Delta}h}{H}.$$

In Equation (3), $k$ is the hydraulic permeability (cm^2^), $\eta$ is the dynamic viscosity of the fluid (Pa.s), $H$ is the sample thickness (cm), $\rho$ is the density of the fluid (g/cm^3^) $g$ is the gravitational acceleration (9.81 m.s^2^), and $\mathsf{\Delta}h$ is the height difference corresponding to a pressure drop $\mathsf{\Delta}P = \rho g\mathsf{\Delta}h$.

Many architectural parameters influence the hydraulic permeability such as the interconnection and the pore size but also the number of interconnections per pore named as "interconnectivity" \[[@B152-pharmaceutics-12-00602]\]. Thereby, hydraulic permeability is directly linked to the structure of porous scaffolds and consequently, to transport properties of the nutrients and oxygen. Small interconnections lower mass transport and thus lead to a reduced oxygen partial pressure to cells. Interestingly, hypoxia can upregulate the matrix production or even induce differentiation of some cell types such as chondrocytes. Kemppainen et al. \[[@B153-pharmaceutics-12-00602]\] showed that scaffolds with small interconnections and subsequently, lower hydraulic permeability can increase the cartilaginous ECM production of chondrocytes.

To conclude this section, cell colonization and vascular growth across porous scaffolds are closely linked to the diameter of the interconnections. The supply of nutrients as well as the removal of cellular wastes are also related to the interconnections and to the interconnectivity by directly affecting the hydraulic permeability. Reduced partial oxygen pressure arising from a lower hydraulic permeability can be advantageous for some cell types such as chondrocytes, which are naturally in a poorly vascularized environment and thus under hypoxic conditions. Cell penetration and cell--cell communication is facilitated, and tissue growth rate is also accelerated in well-interconnected scaffolds.

4.4. The Effect of the Curvature {#sec4dot4-pharmaceutics-12-00602}
--------------------------------

Cells are sensitive to topographical cues such as roughness but also to the curvature of their substrate. Accordingly, the curved surface provided by porous scaffolds appears as an additional feature which can be involved in the regulation of cell functions. Rumpler et al. \[[@B154-pharmaceutics-12-00602]\] demonstrated that the early stages of osteoblasts growth was faster in areas having a high local curvature when cultured in hydroxyapatite (HA) plates with different geometries, either convex, concave of flat surfaces ([Figure 6](#pharmaceutics-12-00602-f006){ref-type="fig"}). This curvature-driven tissue growth looks similar to fluids whose surface tension drives the minimization of the interface. Moreover, F-actin filaments showed different organization with respect to the local curvature which was attributed to curvature-induced forces exerted on the cytoskeleton which may subsequently accelerate the tissue grow rate \[[@B155-pharmaceutics-12-00602]\]. The formation of blood vessels is also accelerated by concave geometries, which is explained by the aggregation of cells leading to the formation of cell--cell contacts involved in the generation of capillaries \[[@B156-pharmaceutics-12-00602]\]. Numerical simulations came at the same conclusion even for scaffolds under flow perfusion \[[@B157-pharmaceutics-12-00602]\]. Besides, this phenomenon of curvotaxis can also be used to manipulate the genetic expression of cells \[[@B158-pharmaceutics-12-00602]\] and it was shown to even overcome the classical contact guidance exerted by the alignment of ECM fibers on cell orientation \[[@B159-pharmaceutics-12-00602]\]. This curvature-driven growth provides a powerful tool to manipulate cell functions without the addition of exogenous factors. Several studies attempted to correlate the tissue formation with a theoretical model which could drive to a predictive manner to anticipate the tissue formation in a given scaffold.

Recently, Buenzli et al. \[[@B160-pharmaceutics-12-00602]\] showed that the improved proliferation of cells on concave surfaces is correlated to the local space availability for cells to grow and to the inhomogeneities in cell density. The confinement experienced in concave areas imposes cells to grow along the normal axis to the surface which subsequently participates in the bridging of the pores of scaffolds. Cell migration was also found to be higher in concave areas based on the argument that the confinement imposed on cells is likely to promote protrusion forces arising from the polymerization of actin filaments pushing against the cell membrane \[[@B161-pharmaceutics-12-00602]\]. Lastly, the current development of platforms that produce scaffolds with highly complex geometries such as 3D printing may be combined with these predictive models.

4.5. Mechanical Properties {#sec4dot5-pharmaceutics-12-00602}
--------------------------

The pioneering work conducted by Engler et al. \[[@B162-pharmaceutics-12-00602]\] demonstrated how to guide the fate of stem cells by tuning the elasticity of a given substrate. Indeed, cells exert either tensile or pulling forces on their substrate while being also sensitive to forces exerted on them which are transmitted through the cytoskeleton and converted to biological signals \[[@B163-pharmaceutics-12-00602]\]. Hence, many studies reported how the influence of changing the Young's modulus of the substrate is connected to the signal transduction pathway \[[@B164-pharmaceutics-12-00602],[@B165-pharmaceutics-12-00602]\]. Therefore, the influence of the Young's modulus of scaffolds was also investigated deeply since mechanotransduction can become an alternative to control the fate of stem cell without the need of soluble molecules such as growth factors. Myoblast cell viability and elongation were higher on scaffold having an E-value of 200 kPa compared to 4, 20, 60, and 280 kPa \[[@B166-pharmaceutics-12-00602]\]. Interestingly, Sridharan et al. \[[@B167-pharmaceutics-12-00602]\] demonstrated that macrophage polarization depends on the stiffness of collagen scaffold but also on the crosslinking agent. Besides, several parts of the body undergo mechanical stresses naturally which is another mechanical solicitation supported by the cells, hence, several researchers developed systems such as bioreactors in order to mimic such conditions. For instance, fibroblasts seeded into a scaffold undergoing mechanical loadings (uniaxial compression) where shown to upregulate their secretions of procollagen type I, fibronectin and MMPs \[[@B168-pharmaceutics-12-00602]\] while MSCs secreted more type I collagen, fibronectin, and lysyl oxidase under cyclic loading \[[@B169-pharmaceutics-12-00602]\]. Nonetheless, Wernike et al. \[[@B170-pharmaceutics-12-00602]\] demonstrated that cyclic loadings can help chondrocytes seeded into a polyurethane scaffold to maintain their phenotype as assessed by type II collagen measurement for short term culture, despite the fact that hypoxia seemed to be more efficient to prevent chondrocyte de-differentiation. While many studies were focused on the macroscopic level of Young's modulus (i.e., of the whole material), cells interact only with their surroundings whose local Young's modulus value can sometimes be smaller than the one of the bulk material \[[@B171-pharmaceutics-12-00602]\]. Nonetheless, Grier et al. \[[@B172-pharmaceutics-12-00602]\] showed that tenocytes are sensitive to the way that collagen-GAG scaffold resisted to contractile forces of cells. Indeed, tenocytes where able to maintain their phenotype on scaffold with the highest degree of crosslinking (i.e., with the highest stiffness) while cells loss their phenotype on scaffold with a smaller degree of crosslinking. The authors showed that the local mechanical properties could be correlated to the macroscopic Young's modulus. Therefore, cells are sensitive to their local environment and geometry, especially for cellular materials such as foams, in which cells can exert bending on the pore walls and struts whose local response to an apply stress differs from that of the whole foam \[[@B173-pharmaceutics-12-00602]\]. For example, Freyman et al. \[[@B174-pharmaceutics-12-00602]\] developed an experimental setup measured the local contractile force exerted by fibroblasts on a collagen-based scaffold. In addition, the role of the matrix viscoelasticity has also become an extensive field of research \[[@B72-pharmaceutics-12-00602]\]. Chaudhuri et al. \[[@B175-pharmaceutics-12-00602]\] demonstrated that MSCs embedded in an alginate hydrogel coupled with cell-adhesive ligands (RGD), and displaying a fast stress relaxation kinetics allows cells to remodel mechanically the fibers increasing locally the RGD ligand density. Thereby, this high ligand density is involved in the signaling pathway, influencing the lineage commitment of stem cells. Moreover, hydrogels non-covalently crosslinked can improve cell spreading through remodeling of the fibers, displaying a viscoelastic behavior \[[@B176-pharmaceutics-12-00602]\].

4.6. Bioactive Scaffolds {#sec4dot6-pharmaceutics-12-00602}
------------------------

Despite the evidence that scaffold structure and mechanical properties can guide cellular response, the complete differentiation into a given phenotype is tightly regulated *in vivo* and often requires the use of bioactive components. Moreover, biochemical cues remain predominant over physical cues to control cell fate \[[@B177-pharmaceutics-12-00602]\]. Known as the third generation of biomaterials, bioactive scaffolds can be loaded with bioactive agents, functionalized, or even based on natural materials such as ECM components in which some biologically relevant functions are intrinsically present. Macroporous scaffolds can be coupled with bioactive compounds which can be released gradually during the degradation of the material or incorporated into vesicles or micro/nanoparticles where their release profile depends on the degradation kinetics of their respective carrier. For instance, incorporation of Nel-like molecule-1 (Nell-1) growth factors in chitosan nanoparticles loaded in an electrospun scaffold allows to maintain the continuous release of growth factors to cells enhancing in a significant way the type II collagen, *SOX9*, and aggrecan expression of hBMSCs consistent with chondrogenic differentiation \[[@B178-pharmaceutics-12-00602]\]. Nanosilicates incorporated in a copolymer based on poly(ethylene oxide terephthalate) (PEOT)/poly(butylene terephthalate) (PBT) (PEOT/PBT) were shown to increase ALP activity of hMSC which indicates an osteogenic differentiation \[[@B179-pharmaceutics-12-00602]\]. Furthermore, Sun et al. \[[@B180-pharmaceutics-12-00602]\] used a computational approach to demonstrate that the pore size of a scaffold plays a role in the release kinetics from the pore walls of growth factors while porosity affects the vascularization and osteogenesis, which implies that scaffold architecture can contribute to modulate the supply of growth factors. Moreover, cell response can also be stimulated through another functionality of the scaffold: the nanoporosity. Firstly, cells can probe their environment at the nanoscale, asperities of substrates are likely felt as ECM fibers \[[@B181-pharmaceutics-12-00602]\] and can guide stem cells toward specific lineages, or conversely, maintain their immunosuppressive phenotype \[[@B182-pharmaceutics-12-00602]\]. Many strategies were developed to implement nanocues into 3D scaffolds as the formation of ECM-like nanofibers through electrospinning \[[@B183-pharmaceutics-12-00602]\]. Secondly, nanopores contribute to increase the bioactivity of Bioglasses by providing a large specific area, thereby, increasing the dissolution rate of Bioglass, which in turn accelerates the formation of an hydroxyapatite layer involved in bone regeneration \[[@B184-pharmaceutics-12-00602],[@B185-pharmaceutics-12-00602]\]. The example of bone is particularly relevant here due to its multiscale and multiphasic features and also due to its hierarchically organized porosity \[[@B186-pharmaceutics-12-00602],[@B187-pharmaceutics-12-00602]\]. Hasan et al. \[[@B188-pharmaceutics-12-00602]\] generated a composite scaffold obtained from carboxymethyl cellulose and chitosan loaded with silver nanoparticles as a multifaceted substrate having both regenerative and antimicrobial properties. However, the controlled release of bioactive molecules is still a challenging task considering the complex spatiotemporal regulation of growth factors in tissues \[[@B189-pharmaceutics-12-00602],[@B190-pharmaceutics-12-00602]\]. Furthermore, complete differentiation of stem cells depends mostly on the combination of several GFs and signals over a certain duration of time (concomitantly or sequentially) \[[@B191-pharmaceutics-12-00602],[@B192-pharmaceutics-12-00602]\]. Moreover, GFs stability is difficult to control and highly sensitive to the external environment such as temperature or pH \[[@B193-pharmaceutics-12-00602]\] and when introduced into the material constituting the scaffold, they can be damaged during the manufacturing process \[[@B194-pharmaceutics-12-00602]\]. Shah et al. \[[@B192-pharmaceutics-12-00602]\] incorporated both hBMP-2 (recombinant human bone morphogenetic protein-2) and angiogenic rhVEGF165 (recombinant human vascular endothelial growth factor) in a polyelectrolyte multilayer allowing to control simultaneously the doses and the release order mediating the formation of a mature bone. Naturally-derived polymer-based scaffolds are biologically active since proteins naturally contain sequences that can be recognized by cell surface receptors to promote the formation of stable focal adhesions \[[@B195-pharmaceutics-12-00602]\] and enzymatically cleavable sequences involved in cell remodeling and migratory processes \[[@B196-pharmaceutics-12-00602]\], or specific sites acting as reservoirs to capture and provide soluble molecules to cells \[[@B197-pharmaceutics-12-00602],[@B198-pharmaceutics-12-00602]\]. For example, self-assembled peptide-based (SAP) hydrogels have a great potential in regenerative medicine since one can generated a highly fibrous assembly which mimics closely the ECM \[[@B199-pharmaceutics-12-00602]\]. Nevertheless, SAP-based hydrogels are mostly composed of di-tri peptides due to complex synthesis steps \[[@B71-pharmaceutics-12-00602]\], limiting their bioactivity compared to systems based on full-length proteins where several functions are incorporated and localized to participate synergistically in the regulation of cell functions \[[@B95-pharmaceutics-12-00602]\]. Supramolecular materials are also one interesting option due to their non-covalent and thus, reversible interactions. Danker et al. \[[@B200-pharmaceutics-12-00602]\] developed a ureido-pyrimidinone-based supramolecular material which can be easily functionalized with bioactive peptides allowing fibroblasts to adhere and which was also degradable. It is noteworthy to mention that the cell--material interaction is mostly indirect \[[@B201-pharmaceutics-12-00602]\]. Indeed, Loebel et al. \[[@B202-pharmaceutics-12-00602]\] showed that hMSCs fate is regulated mostly by their adhesion and remodeling to their own secreted proteins when encapsulated into HA hydrogels implying that the scaffold-mediated cell regulation depends on how secreted ECM components are adsorbed onto the fibers of the hydrogel. One step further in the imitation of the ECM can be achieved by self-healing hydrogels to account for the dynamic and constant remodeling of tissues \[[@B203-pharmaceutics-12-00602]\]. This ability to recover its integrity relies mostly on the supramolecular interactions allowing cells to remodel the fibers network while other broken bonds can be reformed allowing to maintain the structural integrity. Additionally, self-healing hydrogels are good candidates for 3D printing technologies unlike classical covalent hydrogels which can be irreversibly damaged during the extrusion process \[[@B204-pharmaceutics-12-00602]\]. Finally, other routes are being investigated to develop stimuli responsive hydrogel-based scaffolds, Liu et al. \[[@B205-pharmaceutics-12-00602]\] generated a chitosan-based hydrogel with glucose oxidase immobilized on the surface as a promising solution for the regulation of glucose level in blood. pH-sensitive hydrogels are also interesting for drug delivery applications \[[@B206-pharmaceutics-12-00602]\].

5. *In Vivo* Outcomes and Clinical Trials {#sec5-pharmaceutics-12-00602}
=========================================

Although tissue regeneration assisted by scaffolds led to promising results *in vitro*, the absence of immune system and the whole cascade of events happening at different timelines is difficult to reproduce artificially. Several studies have already been conducted *in vivo*, and the aim of this section is to summarize the main results where the relationship between the scaffold structure and cell response or tissue integration has been explored in order to identify the principal successes and the remaining issues to tackle.

Following the same trend as for *in vitro* studies, the influence of structural parameters like pore and interconnection sizes has also been investigated in animals. Van Tienen et al. \[[@B207-pharmaceutics-12-00602]\] produced polyurethane foams having a bi-modal pore size distribution: larger pores with diameters ranging between 150 and 300 µm and smaller pores whose diameters were either in the range of 15--20 µm or above 30 µm. These two types of scaffolds had porosity values of 73 and 86% where the highest value of porosity was found for the scaffold with the largest micropores (\>30µm). Results after implantation in rats showed that more tissue was formed in the scaffold with larger micropores. A 6 months study was also conducted in dog meniscus where a polyurethane scaffold was placed. The diameter of the pores was in the 150--355 µm range while the interconnection diameters were below 50 µm. A fibrovascular tissue was formed within the scaffold as a consequence of the FBR confirmed by giant cells at the implant site. The FBR was attributed to the polyurethane--macrophages interaction and results were variable between each animal \[[@B207-pharmaceutics-12-00602]\]. Moreover, structures with sharper pore size distributions seem to enhance tissue ingrowth *in vivo* \[[@B208-pharmaceutics-12-00602]\]. Furthermore, dendritic cell maturation was found to be higher in scaffolds with pore diameter of 40 µm compared to 90 µm, which led to a collagenous and avascular tissue \[[@B209-pharmaceutics-12-00602]\]. Accordingly, the suitable range regarding the pore size seems to follow the same trend *in vivo* and *in vitro*, namely, few hundreds of microns, while positive outcomes regarding immune cell maturation occur preferably for pore size below 100 µm.

The effect of the interconnection diameter was also evaluated. A series of porous β-TCP scaffolds were produced by Feng et al. with pore diameter gradually increasing between 300 and 700 µm with interconnection diameter fixed at 120 µm and constant porosity (70%). After 4 weeks of implantation in rabbits, the authors found that the extend of fibrovascular tissue was inversely proportional to the pore diameter. They argued that smaller diameters (i.e., larger local curvature) accelerate the tissue growth through a curvature-driven mechanism \[[@B210-pharmaceutics-12-00602]\]. In previous studies, we demonstrated also that the cellular filling of implant consisting in an assembly of titanium microbeads is facilitated with smaller beads despite these surfaces were convex, cell bridging, and cell--cell contacts were favored \[[@B211-pharmaceutics-12-00602],[@B212-pharmaceutics-12-00602]\]. Besides, a scaffold with a higher number of interconnections (i.e., the interconnectivity) shows a significant improvement of osteogenesis in rabbits compared to the same scaffold with a limited number of interconnections \[[@B213-pharmaceutics-12-00602]\]. This result was attributed to the larger surface area, which provides more available space for cell attachment, while degrading faster which also improves the resorption of the scaffold.

Two main routes are followed in scaffold-based strategies, namely: pre-cellularized scaffolds with autologous cells as a strategy to reduce rejections \[[@B214-pharmaceutics-12-00602]\], and more recently, cell-free scaffolds which are under consideration since they are classified as "medical devices" according to the U.S Food and Drug Administration (FDA) standards, thus, their clinical applications could be faster \[[@B215-pharmaceutics-12-00602]\]. For instance, bone ingrowth was improved in cell-free porous Ti6Al4V scaffold having a pore size of 300--400 µm after 1 year of implantation in goat bone defect \[[@B216-pharmaceutics-12-00602]\]. However, scaffolds seeded with articular chondrocytes were more efficient compared to cell-free scaffolds for meniscus regeneration in rabbits \[[@B217-pharmaceutics-12-00602]\].

Recently, a bioprinter was also designed to print in-situ a sheet composed of biopolymers for wound dressing in porcine model ([Figure 7](#pharmaceutics-12-00602-f007){ref-type="fig"}). The printed biomaterial stopped more rapidly bleeding but its regenerative potential was not studied yet \[[@B218-pharmaceutics-12-00602]\]. This technology is highly versatile and allows to print either a single or several different layers of various biopolymers, pre-colonized or not, which has a great potential.

Some drug-releasing scaffolds were also tested in animals recently by Fadia et al. \[[@B219-pharmaceutics-12-00602]\] which accomplished nerve regeneration in monkeys within a PCL tube coated with microspheres releasing glial cell line--derived neurotrophic factors (GDNF). Very recently, an SAP-based hydrogel, whose chemistry involved a combination of both non-covalent and covalent bonds was generated and allowed for the remodeling and the robustness to stimulate bone regeneration in rabbits. The chosen peptide sequence contributed to high water retention and stimulated the formation of blood vessels. Moreover, the gel was injectable, which avoids any extensive surgery \[[@B220-pharmaceutics-12-00602]\].

Clinical trials related to the implantation of scaffolds remain rather rare, and this can be explained by the complex regulatory and by the fact that the development of a functional scaffold is expensive. Furthermore, animal studies cannot necessarily be extrapolated into humans accurately even if they are mandatory \[[@B221-pharmaceutics-12-00602]\]. Nonetheless, commercialized scaffolds do already exist. Scaffolds developed for the treatment of foot ulcers based on collagen (Apligraf^®^) or polyglactin (Dermagraft^®^) (Organogenesis. Inc) allowed a successful tissue ingrowth \[[@B222-pharmaceutics-12-00602],[@B223-pharmaceutics-12-00602]\]. Besides, Integra^®^ (Integra Lifesciences) is a skin substitute based on a top layer composed of the association of a GAG and collagen supported by a silicon layer \[[@B224-pharmaceutics-12-00602]\]. Researchers from our lab conceived an implant based on porous titanium for larynx replacement \[[@B225-pharmaceutics-12-00602]\]. A 16-month follow-up showed that the patient recovered swallowing and whispering capacities thanks to the artificial larynx.

Furthermore, scaffolds based on polyurethane were developed as a meniscus substitute (Actifit) \[[@B226-pharmaceutics-12-00602]\]. After at least five years post-implantation, MRI scans revealed that cartilage remained mostly immature even though functional scores were suitable. However, the pain felt by some patients was too high to continue the study. A collagenous scaffold was implanted in five patients having a spinal cord defect, where two out of five patients showed partial neural regeneration, which was attributed to the favorable environment provided by the scaffold \[[@B227-pharmaceutics-12-00602]\]. Furthermore, a polymeric scaffold made by a combination of lactic-co-glycolic acid and poly(L-lysine) prepared by salt leaching process did not induce any complication after 6 months in a patient. The scaffold was implanted at a spinal cord defect and a slight improvement of sensorimotor functions was noticed \[[@B228-pharmaceutics-12-00602]\]. Although it is not clearly mentioned, the absence of inflammatory complication could be correlated with the pore size which was shown to prevent the penetration of fibroblasts that are involved in the formation of scar tissues \[[@B229-pharmaceutics-12-00602]\]. In another clinical study, bioactive glass having both nanopores and micropores showed that alveolar bone remodeling was improved at the pocket resulting from tooth extraction. The addition of nanopores within the structure contributed to increase the surface area and therefore, to the dissolution whose products participate in the remodeling process \[[@B230-pharmaceutics-12-00602]\]. A SAP-based hydrogel named P~11~-4 showed to behave as a nucleation agent in the formation of hydroxyapatite and showed in caries lesion treatments, enamel regeneration in humans \[[@B231-pharmaceutics-12-00602]\], this same system also promoted regeneration of rat bone cranial defects after 6 weeks \[[@B232-pharmaceutics-12-00602]\].

It turns out that in several studies, tissue in-growth within the porous scaffold is not a limitation *in vivo* conversely to *in vitro* where the lack of interstitial fluid and blood stream together with the absence of chemotactic gradient may limit the migration potential of the cells at the center of the scaffold. However, *in vivo* and especially in clinical trials, the neo tissue is often fibrotic and non-functional potentially leading to implant failure. This deficiency comes from the inflammatory process whose evolution deviates from the normal wound healing cascade due to the presence of the foreign body. Immune cells such as macrophages play a leading role in the healing process. Indeed, macrophage polarization, either M1 which is attributed to a pro inflammatory pathway or M2 known as pro regenerative \[[@B233-pharmaceutics-12-00602]\] are key elements influencing the cascade of events after implantation \[[@B234-pharmaceutics-12-00602]\]. Scaffolds with an average pore diameter of 40 µm can induce a shift in macrophage polarization from M1 to M2 type leading to a decrease of the FBR associated with a higher vascularization 4 weeks post implantation in rats \[[@B145-pharmaceutics-12-00602]\]. This discovery provides the opportunity to modulate macrophage polarization and therefore, the host response to implants at the early stages via pore diameters. Several studies agreed on a limit diameter of the pores of the scaffolds set at 80 µm above which the fibrous capsule is increased and less blood vessels are formed within the scaffolds \[[@B39-pharmaceutics-12-00602],[@B235-pharmaceutics-12-00602]\]. Sadtler et al. \[[@B236-pharmaceutics-12-00602]\] demonstrated that the shift toward M2 lineage depends on the presence of T-helpers 2 cells at the implant site which secreted IL4, which is subsequently involved in the M2 commitment of macrophages.

6. General Conclusion and Future Perspectives {#sec6-pharmaceutics-12-00602}
=============================================

In the view of the literature, some general trends and agreements can be extracted regarding the structural parameters of scaffolds. First, pore size from a few hundred microns are mostly defined as the most suitable to guarantee an access to nutrients for cells. Moreover, porosity values are also usually found above 70%, which provides space for cell infiltration and mass transport while providing enough material for initial cell attachment. Interconnection size is also a key element affecting transport properties throughout the porous structure and one acceptable consensus seems to converge around 50 µm as minimum to allow blood vessels formation and cell migration. Physical cues such as the material stiffness, its viscoelasticity, or pore curvature can participate in the regulation of cell differentiation and functions but the effect of endogenous factors such as GFs, hormones or cytokines remains stronger to drive cell fate toward a fully mature state. Nevertheless, the complex regulation of signaling molecules in tissues is hard to reproduce artificially, taking into account the spatio-temporal and multicomponent-dependent supply of bioactive molecules. Platforms allowing a combinatorial provision of both physical and chemical cues are relevant approaches to address this issue \[[@B177-pharmaceutics-12-00602],[@B237-pharmaceutics-12-00602]\]. This raises the question of the complexity to process scaffolds having various functionalities and being able to evolve and to adapt to the dynamic process of wound healing encountered in biological environments, and accordingly, their associated cost to develop such systems. Moreover, most of the studies performed *in vitro* consist of seeding cells (either stem cells or adult cells) into a porous scaffold and looking at the influence of one or several components on those cells. *In vivo*, immune cells such as neutrophils, monocytes, and later on, macrophages are more likely the first cells that come in contact with the scaffold, therefore, these cells subsequently, adhere, and secrete cytokines to recruit other actors whereas the migration and differentiation of stem cells at the site of implantation corresponds only to the later stages of the healing process. For example, Barthes et al. \[[@B238-pharmaceutics-12-00602]\] recently modified the surface of titanium microbeads to diminish macrophage adhesion, while increasing fibroblasts colonization at the same time. Consequently, the state of the scaffold (i.e., the protein type adsorbed onto the surface and the cells already present) may probably be different from the one of the raw scaffolds freshly generated and immersed in culture medium *in vitro*. Such discrepancies were already pointed out in the evaluation of the pore size influence on macrophage polarization and their subsequent influence on the capsule formation. Indeed, pore size below 100 µm appears as preferable. *In vivo* outcomes also support these trends since implanted scaffolds are often filled with scar tissues with low functionality and as a consequence of the foreign body reaction \[[@B239-pharmaceutics-12-00602]\]. Furthermore, the immune cascade is also patient-dependent, emphasizing the need to orient future research toward more personalized scaffolds as recently stressed by Vrana et al. \[[@B240-pharmaceutics-12-00602]\].
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![Illustration of the electrospinning process (**a**). Taken with permission from Li et al. \[[@B55-pharmaceutics-12-00602]\] SEM images showing the fiber assembly either randomized (**b**) or aligned (**c**), adapted with permission from Ndreu et al. \[[@B11-pharmaceutics-12-00602]\]. (**d**) Illustration of particle leaching process with the template formation (1) followed by matrix pouring (2) and particle dissolution (3) taken from Lutzweiler \[[@B56-pharmaceutics-12-00602]\], SEM images of scaffolds generated by chemical foaming (**e**) taken with permission from Ng et al. \[[@B57-pharmaceutics-12-00602]\], particle leaching using salt (**f**) taken with permission from Janik et al. \[[@B58-pharmaceutics-12-00602]\], sphere templating (**g**) taken with permission from Choi et al. \[[@B59-pharmaceutics-12-00602]\], and microfluidics (**h**) reused with permission from Testouri et al. \[[@B48-pharmaceutics-12-00602]\].](pharmaceutics-12-00602-g001){#pharmaceutics-12-00602-f001}

![Carboxybetaine methacrylamide (CBMAA)-based porous hydrogel having a gyroid structure. The structure is visualized using a confocal microscope where FITC-BSA is adsorbed on the surface. Adapted with permission from Kostina et al. \[[@B79-pharmaceutics-12-00602]\].](pharmaceutics-12-00602-g002){#pharmaceutics-12-00602-f002}

![Proposed arrangement of self-assembled peptides (SAP)-based hydrogel from the tetrapeptide (H2N-Gly-Phe-Ile-Leu-COOH) where weak interactions as hydrogen bonding and π-π interactions govern the cross-*β* structure. Reprinted with permission from Naskar et al. \[[@B107-pharmaceutics-12-00602]\]. Copyrights (2020) American Chemical Society.](pharmaceutics-12-00602-g003){#pharmaceutics-12-00602-f003}

![Examples of unit cell design with triply periodic minimal structures (TPMS) with various relative densities ($\rho_{s}/\rho_{b}$) as potential scaffolds for tissue engineering. Adapted with permission from Montazerian et al. \[[@B137-pharmaceutics-12-00602]\].](pharmaceutics-12-00602-g004){#pharmaceutics-12-00602-f004}

![(**a**) SEM image of a porous scaffold produced by sphere templating where "D" indicates the pore diameter and "d" the interconnection diameter (Image taken by G. Lutzweiler). (**b**) Evolution of the blood vessels within a porous scaffold as a function of time with varying interconnection diameters (100, 120, and 150 µm). Adapted from Xiao et al. \[[@B149-pharmaceutics-12-00602]\] (Creative Commons CC BY).](pharmaceutics-12-00602-g005){#pharmaceutics-12-00602-f005}

![(**a**) Top images show osteoblasts seeded in four different HA plates with various geometries after 21 days (i--iii) and 30 days (iv) to images taken after 21 days of culture and (iv) at 30 days compared with numerical simulations at the bottom. (**b**) F-actin filaments (green) are more disordered in areas with high curvature (close to the edge of the triangle) whereas they are more aligned near the tissue/fluid interface (all images adapted from Rumpler et al. \[[@B154-pharmaceutics-12-00602]\], Creative Commons Attribution License).](pharmaceutics-12-00602-g006){#pharmaceutics-12-00602-f006}

![(**a**) Photograph of the printing of a biopolymer sheet in porcine wound. (**b**) Difference between the control (without biopolymer sheet) and the wound filled with a biopolymer sheet after 5 min. Scale bar: 2 mm. (**c**) Re-epithelialization assessed by trichrome staining between control (top images) and wound filled with biopolymer sheet (bottom images), scale bar 2 mm (left), and 1 mm (right). Adapted with permission from Hakimi et al. \[[@B218-pharmaceutics-12-00602]\].](pharmaceutics-12-00602-g007){#pharmaceutics-12-00602-f007}
